Press Release


Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
Mar 25, 2020 08:38 JST
Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ.
More info..

Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
Mar 23, 2020 10:53 JST
Eisai Co., Ltd. announced today that it will launch "NouKNOWTM", a new digital tool (non-medical device) for self-assessment of brain performance (brain health).
More info..

Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan
Mar 19, 2020 14:15 JST
EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families.
More info..

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Feb 25, 2020 08:10 JST
Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.
More info..

Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
Feb 21, 2020 16:55 JST
Eisai Co., Ltd. announced today that it received the President's Award at the 8th Technology Management and Innovation Awards held by the Japan Techno-Economics Society (JATES).
More info..

Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc. Using Liquid Biopsy to Accelerate Next-Generation Drug Discovery and Development
Jan 29, 2020 07:37 JST
Eisai Co., Ltd. announced today that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research.
More info..

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan
Jan 23, 2020 14:57 JST
Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia.
More info..

Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
Jan 23, 2020 14:46 JST
The approval for monotherapy for partial-onset seizures is based on the results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea.
More info..

Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019
Jan 20, 2020 14:21 JST
Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP, a non-profit organization, as a company that has performed particularly well in response to climate change.
More info..

Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China
Jan 06, 2020 08:57 JST
Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.
More info..

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
Dec 24, 2019 16:22 JST
Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications.
More info..

U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients
Dec 23, 2019 08:17 JST
Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant).
More info..

Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World
Dec 10, 2019 08:02 JST
Eisai Co., Ltd. announced today that Eisai had a groundbreaking ceremony for a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan) as part of strategic investment to realize Eisai's medium-term business plan "EWAY2025."
More info..

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
Dec 09, 2019 08:36 JST
Sysmex Corporation and Eisai Co., Ltd. are pursuing a joint project to develop a method of diagnosing Alzheimer's disease (AD) using blood, presented two posters showing the most recent data from the project.
More info..

Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
Dec 09, 2019 08:17 JST
Eisai Co., Ltd. has received a notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the orally available kinase inhibitor LENVIMA (lenvatinib) in treatment of thyroid cancer has been cleared.
More info..

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Dec 05, 2019 08:11 JST
The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.
More info..

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019 08:23 JST
BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.
More info..

Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China
Dec 02, 2019 08:08 JST
Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of differentiated thyroid cancer.
More info..

Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting
Nov 26, 2019 08:37 JST
Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.
More info..

Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
Nov 20, 2019 13:01 JST
Eisai Co., Ltd. announced today that it has launched the Equfina 50mg TABLETS for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan.
More info..

Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Nov 05, 2019 09:02 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.
More info..

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 10:13 JST
Biogen and Eisai, Co., Ltd. has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD).
More info..

Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 15, 2019 20:24 JST
Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.
More info..

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Oct 01, 2019 10:46 JST
The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).
More info..

Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Sep 30, 2019 11:06 JST
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
More info..

Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Sep 26, 2019 13:21 JST
Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
More info..

Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
Sep 26, 2019 13:08 JST
Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
Sep 24, 2019 09:01 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019.
More info..

Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
Sep 20, 2019 15:13 JST
In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide.
More info..

Latest Release


More Latest Release >>